Are β-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction?

Background: Although randomized clinical trials have demonstrated that b-blocker therapy is effective in reducing mortality after acute myocardial infarction (AMI), many of these studies excluded patients who undergo coronary revascularization. However, the clinical practice guidelines established by the American College of Cardiology and the American Heart Association recommend that b-blocker therapy be considered for patients who underwent successful revascularization after AMI. Methods: Using data from the Cooperative Cardiovascular Project, we compared the initiation of b-blocker therapy at discharge in patients aged 65 years or older who underwent coronary artery bypass surgery (CABG) or percutaneous transluminal coronary angioplasty (PTCA) during their hospitalization for AMI with that of patients who did not undergo revascularization. We then examined whether b-blocker therapy was associated with lower 1-year mortality between revascularized and nonrevascularized groups. Results: After excluding patients with contraindications to b-blocker therapy, 84 457 patients remained in the study sample. Of these, 8482 patients underwent CABG, and 13 997 patients underwent PTCA. After adjusting for demographic and clinical factors, we found that these patients were less likely to initiate b-blocker therapy after CABG (odds ratio [OR], 0.44; 95% confidence interval [CI], 0.41-0.47) or PTCA (OR, 0.89; 95% CI, 0.85-0.93) relative to the nonrevascularized group. After adjusting for potential confounders, b-blockers were significantly associated with lower 1-year mortality in patients who underwent CABG (hazard ratio [HR], 0.70; 95% CI, 0.55-0.89) or PTCA (HR, 0.86; 95% CI, 0.74-1.00), similar to that of the nonrevascularized group (HR, 0.83; 95% CI, 0.80-0.87). Conclusions: Therapy after AMI with b-blockers appears to be as effective in reducing 1-year mortality for elderly patients who have undergone CABG or PTCA as for a nonrevascularized group. Our findings suggest that routine use of b-blockers should be considered for patients who undergo revascularization after AMI. Arch Intern Med. 2000;160:947-952

[1]  R. Califf,et al.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[2]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[3]  H. Krumholz,et al.  National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. , 1998, JAMA.

[4]  H. Krumholz,et al.  Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. , 1998, JAMA.

[5]  E. Huff,et al.  Comprehensive reliability assessment and comparison of quality indicators and their components. , 1997, Journal of clinical epidemiology.

[6]  R. Califf,et al.  Outcome of acute myocardial infarction according to the specialty of the admitting physician. , 1996, The New England journal of medicine.

[7]  Richard P. Lewis,et al.  ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[8]  J. Herlitz.  The MACB Study Group. Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting , 1995 .

[9]  E. Fisher,et al.  Studying Outcomes and Hospital Utilization in the Elderly: The Advantages of a Merged Data Base for Medicare and Veterans Affairs Hospitals , 1992, Medical care.

[10]  R. Marinchak,et al.  Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. , 1992, The American journal of cardiology.

[11]  E. Antman,et al.  Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. , 1991, Circulation.

[12]  H. Emanuelsson,et al.  Role of beta-adrenergic blockers after percutaneous transluminal coronary angioplasty. , 1990, The American journal of cardiology.

[13]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[14]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[15]  K. Swedberg,et al.  EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised Trial , 1981, The Lancet.

[16]  R. Frater,et al.  Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 10. Beta-adrenoceptor blockade and coronary artery surgery. , 1980, American heart journal.